Alberto Mussetti
LightNews LightNews
banner
albertomussetti.bsky.social
Alberto Mussetti
@albertomussetti.bsky.social
27 followers 59 following 72 posts
Director #HCT and #CART therapy Institut Català d'Oncologia, L' Hospitalet de Llobregat, Barcelona. #digitalmedicine #lymphoma #AI.

https://www.enciclopedia.cat/divulcat/Alberto-Mussetti

https://albertomussetti.substack.com/
Posts Replies Media Videos
albertomussetti.bsky.social
Artificial intelligence in hematology url: ashpublications.org/blood/articl...
Artificial intelligence in hematology
In the last 2 years, the capabilities of artificial intelligence (AI) have progressed rapidly and are increasingly being integrated into hematology practic
ashpublications.org
November 6, 2025 at 10:55 PM
albertomussetti.bsky.social
A BCMA-mRNA vaccine is a promising therapeutic for multiple myeloma url: ashpublications.org/blood/articl...
A BCMA-mRNA vaccine is a promising therapeutic for multiple myeloma
Key PointsWe developed a therapeutic cancer vaccine for MM against BCMA.Our findings revealed BCMA-specific immune response, providing the framework for it
ashpublications.org
November 6, 2025 at 10:54 PM
albertomussetti.bsky.social
Older matched sibling donor vs young haploidentical donor for older patients with acute myeloid leukemia url: ashpublications.org/bloodadvance...
Older matched sibling donor vs young haploidentical donor for older patients with acute myeloid leukemia
Key PointsOlder MSDs or young HIDs lead to similar survival in older patients with AML.Young HID is associated with less relapse, whereas older MSD is asso
ashpublications.org
November 4, 2025 at 8:46 PM
albertomussetti.bsky.social
Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis url: ashpublications.org/bloodadvance...
Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis
Key PointsReal-world effectiveness and safety outcomes in patients with R/R MCL treated with brexu-cel are similar to those of the ZUMA-2 trial.The benefit
ashpublications.org
October 29, 2025 at 12:48 AM
albertomussetti.bsky.social
www.nature.com/articles/s41...
Microenvironmental regulation of solid tumour resistance to CAR T cell therapy - Nature Reviews Immunology
The tumour microenvironment (TME) poses a significant obstacle to the success of chimeric antigen receptor (CAR) T cell immunotherapy in solid tumours. Here, the authors detail how both cellular and n...
www.nature.com
October 18, 2025 at 9:56 AM
albertomussetti.bsky.social
Germline determinants of toxicity and efficacy in patients with large B-cell lymphoma treated with CAR T-cell therapy jitc.bmj.com/content/13/1...
Germline determinants of toxicity and efficacy in patients with large B-cell lymphoma treated with CAR T-cell therapy
Background Recent data have suggested that germline genetic aberrations can affect outcomes in patients with large B-cell lymphoma (LBCL) treated with chimeric antigen receptor T-cell therapy (CART). ...
jitc.bmj.com
October 12, 2025 at 5:23 PM
albertomussetti.bsky.social
CD19 CAR T-Cell Therapy in Multidrug-Resistant Ulcerative Colitis | New England Journal of Medicine DOI: 10.1056/NEJMc2508023
September 25, 2025 at 12:09 PM
albertomussetti.bsky.social
24th OCT 2025 - Barcelona

Join the #1 edition of "AICT: Artificial Intelligence & Cell Therapy" – where tech meets hematology 🧠🧬
🚀 free inscription, In-person and online.

#AICT2025 #CellTherapy #AIinMedicine #FutureIsNow #CART #HCT #digitalhealth #digitalrevolution

lnkd.in/dBDXnaSK
www.geth.es
September 18, 2025 at 3:09 PM
albertomussetti.bsky.social
mRNA for CART manufacturing for LES...

www.nejm.org/doi/full/10....
In Vivo CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus | NEJM
In patients with refractory systemic lupus erythematosus, in vivo generation of CD19 CAR T cells by means of lipid nanoparticles led to B-cell depletion, reduced disease activity, and no major toxi...
www.nejm.org
September 18, 2025 at 3:01 PM
albertomussetti.bsky.social
Augmented CD47 expression impairs alloreactive T-cell clearance after allo-HCT url: ashpublications.org/blood/articl...
Augmented CD47 expression impairs alloreactive T-cell clearance after allo-HCT
Key PointsAugmented CD47 expression on alloreactive donor T cells after HCT inhibits their phagocytosis by macrophages.Anti-CD47 treatment boosts phagocyto
ashpublications.org
September 11, 2025 at 8:34 PM
albertomussetti.bsky.social
Transformative Research in Cystic Fibrosis | New England Journal of Medicine www-nejm-org.sire.ub.edu/doi/full/10....
Shibboleth Authentication Request
www-nejm-org.sire.ub.edu
September 11, 2025 at 2:36 PM
albertomussetti.bsky.social
Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies url: ashpublications.org/blood/articl...
Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies
Key PointsWU-CART-007, an allogeneic anti-CD7 chimeric antigen receptor T cell, established a manageable safety profile at the RP2D of 900 × 106 cells.WU-C
ashpublications.org
September 4, 2025 at 8:08 PM
albertomussetti.bsky.social
ashpublications.org/bloodadvance...
A prospective clinical trial of GVHD prophylaxis with posttransplant cyclophosphamide and abatacept
Key PointsPTCy+Aba arm is associated with less chronic GVHD and a favorable GRFS compared with methotrexate/tacrolimus.PTCy and Aba without a calcineurin i
ashpublications.org
September 2, 2025 at 6:57 PM
albertomussetti.bsky.social
Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma url: ashpublications.org/blood/articl...
Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma
Key PointsDespite similar CAR T-cell dynamics, patients with SLE experienced less severe adverse events after CAR T-cell therapy than those with B-NHL.In p
ashpublications.org
August 28, 2025 at 8:11 PM
albertomussetti.bsky.social
www.cell.com/cancer-cell/...
Lymphoma accelerates T cell and tissue aging
Hesterberg et al. show that lymphoma provokes marked and rapid changes in young T cells that recapitulate the transcriptional, epigenetic, and senescent features manifest in aged T cells, including ag...
www.cell.com
August 27, 2025 at 1:59 PM
albertomussetti.bsky.social
www.mdanderson.org/newsroom/nov...
Novel tool helps identify key targets to strengthen CAR NK cell therapies
Natural killer (NK) cells became markedly better at killing cancer cells after scientists removed key gene targets identified through a new genome-wide CRISPR screening tool, according to new research...
www.mdanderson.org
August 25, 2025 at 1:14 PM
albertomussetti.bsky.social
www.nytimes.com/2025/08/25/m...
What Does It Take to Get Men to See a Doctor?
www.nytimes.com
August 25, 2025 at 1:11 PM
albertomussetti.bsky.social
www.nejm.org/doi/full/10....
Educational Strategies for Clinical Supervision of Artificial Intelligence Use | NEJM
Many learners are more facile with the use of large language models in medicine than their supervisors are. The authors provide an approach to clinical supervision that can mitigate the perils and ...
www.nejm.org
August 20, 2025 at 10:18 PM
albertomussetti.bsky.social
www.nejm.org/doi/full/10....
Targeted Therapy of CAR+ T-Cell Lymphoma after Anti-BCMA CAR T-Cell Therapy | NEJM
A rare T-cell lymphoma after chimeric antigen receptor (CAR) T-cell therapy for myeloma was linked to CCR4 overexpression and vector integration, which highlights the need for monitoring after CAR ...
www.nejm.org
August 20, 2025 at 10:12 PM
albertomussetti.bsky.social
jitc.bmj.com/content/13/8...
Zelig Eshhar (1941–2025): a tribute for a life for immunotherapy
Zelig Eshhar, PhD, Fellow of the Academy of Immuno-Oncology (FAIO), passed away on July 3, 2025, at the age of 84. His passing is deeply personal to all of us and for the entire field of cancer immuno...
jitc.bmj.com
August 10, 2025 at 5:02 PM
albertomussetti.bsky.social
www.ara.cat/1_535642
Que la IA et diagnostiqui: el ChatGPT que ja fa servir el teu metge
L'eina estarà a prova aquest any per donar suport als professionals sanitaris en la presa de decisions
www.ara.cat
August 5, 2025 at 1:03 PM
albertomussetti.bsky.social
www.nytimes.com/2025/08/04/o...
Opinion | You Are Contaminated
www.nytimes.com
August 4, 2025 at 5:03 PM
albertomussetti.bsky.social
www.nytimes.com/2025/07/31/w...
Could Dementia Patients Benefit from an A.I. Companion?
www.nytimes.com
August 3, 2025 at 4:17 PM
albertomussetti.bsky.social
Heterogeneity of high-potency multilineage hematopoietic stem cells and identification of “Super” transplantability url: ashpublications.org/blood/articl...
Heterogeneity of high-potency multilineage hematopoietic stem cells and identification of “Super” transplantability
Key PointsUnique molecular features of Super-class HSCs were identified through analyses of single-clone serial transplants.Low expression of CD27 is a key
ashpublications.org
July 31, 2025 at 6:07 PM
albertomussetti.bsky.social
Dear friends and colleagues,

We would love to have you join this year’s Transplant Complications Working Party Educational Meeting in Dubrovnik, Croatia, on the 1st-3rd of October. The EBMT

More information here:

www.ebmt.org/events/trans...

We look forward to seeing you in Dubrovnik!
LinkedIn
This link will take you to a page that’s not on LinkedIn
lnkd.in
July 28, 2025 at 4:03 PM